 This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major complications including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation in the first 30 days after surgery. 